

【CLAIMS】**【Claim 1】**

An oral pharmaceutical formulation comprising pantoprazole formed by a direct enteric coating layer comprising an enteric polymer and polyethylene glycol as an essential plasticizer, on a core containing pantoprazole or its alkaline metal salts as an active ingredient.

【Claim 2】

The oral pharmaceutical formulation comprising pantoprazole according to claim 1, wherein its core contains a low-viscosity hydroxypropylmethyl cellulose as a binder, lactose as a diluent, and crospovidone as a disintegrant.

【Claim 3】

The oral pharmaceutical formulation comprising pantoprazole according to claim 1, wherein the enteric polymer is methacrylic acid copolymer.

【Claim 4】

A method for manufacturing the oral pharmaceutical formulation comprising pantoprazole prepared by a process which includes forming a core comprising pantoprazole or its alkaline metal salts;

dissolving or suspending an enteric polymer and polyethylene glycol as an essential plasticizer in a solvent to prepare an enteric suspension;

and spraying the enteric suspension to the core to form an enteric coating layer, wherein another intermediate layer is not formed between the core and enteric coating layer.

【Claim 5】

The method for manufacturing the oral pharmaceutical formulation comprising pantoprazole according to claim 4, wherein its core contains a low-viscosity hydroxypropylmethyl cellulose as a binder, lactose as a

diluent, and crospovidone as a disintegrant.

【Claim 6】

The method for manufacturing the oral pharmaceutical formulation comprising pantoprazole according to claim 4, wherein the enteric polymer is methacrylic acid copolymer.